Therapeutic usefulness of amitriptyline in spastic colon syndrome.
The therapeutic efficacy of amitriptyline in irritable bowel was studied in a cross-over double-blind trial, employing fourteen patients whose symptoms were rated as Class II or worse on an arbitrarily-defined interval scale and who had not benefited from previous trials of anticholinergics, anticholinergic-sedative combinations, and bulk-forming agents. During the study, patients rated their own symptoms and the interviewer rated their symptoms using the same scale. Average scores for the patients while on drug showed significant improvement compared to pre-test level. No placebo or drug carry-over effects could be demonstrated. Inasmuch as amitriptyline is effective in this context at dosages subtherapeutic with regard to depression, the authors suggest that a central (perhaps anticholinergic) mechanism of action is responsible.
D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008950:MMPI; D008297:Male; D008875:Middle Aged; D010919:Placebos
D010919:Placebos; D000639:Amitriptyline